Introduction
============

Warfarin is an oral anticoagulant prescribed for the prevention and treatment of thrombotic disorders and is indicated for thrombotic disorders such as atrial fibrillation, heart valve replacement, history of thrombosis, and post-orthopedic surgery.[@b1-pgpm-12-015] It is clinically available as a racemic mixture of R and S isomers, where the S-isoform has a potent activity 2--5 times higher than the R-isoform and is metabolized mainly by the CYP/CYP450 2C9 enzyme (*CYP2C9*) in the liver.[@b1-pgpm-12-015],[@b2-pgpm-12-015]

The ability of warfarin to act as an anticoagulant stems from its deactivation of the vitamin K epoxide reductase C complex (*VKORC1*), regenerating the reduced form of vitamin K that is necessary for the activation of coagulation factors.[@b1-pgpm-12-015],[@b3-pgpm-12-015],[@b4-pgpm-12-015] The efficacy and safety of warfarin depend mainly on the maintenance of prothrombin time, represented by the international normalized ratio (INR), within the therapeutic range. Analysis of many studies has shown that higher INR values are related to an increased risk of hemorrhage, while a lower INR value leads to a high risk of thromboembolism or stroke.[@b5-pgpm-12-015]--[@b8-pgpm-12-015] However, reaching the target INR may take weeks, increasing the risk of adverse drug events during the initial phase of therapy.[@b9-pgpm-12-015]

Knowing the extent to which genetic and environmental factors affect the anticoagulant response might help predict more individualized warfarin doses, resulting in a more accurate and safe anticoagulation therapy.[@b10-pgpm-12-015] In the late 2000s, the United States Food and Drug Administration announced that the warfarin label stat (which describes patients' therapeutic dosage) had to underline its pharmacogenetic activity, particularly in patients with *VKORC1* 1, 639G\>A, *CYP2C9* \* 2, and *CYP2C9* \* 3 polymorphisms.[@b11-pgpm-12-015]--[@b13-pgpm-12-015]

Polymorphisms in genes encoding metabolic enzymes, transporters, and drug receptors can modulate warfarin response.[@b14-pgpm-12-015] Correspondingly, pharmacogenetic analysis of two genes, *CYP2C9* and *VKORC1*, suggests that their genetic variants strongly influence the individual response to warfarin.[@b3-pgpm-12-015] *CYP2C9* metabolizes almost 25% of all clinical medications, and genetic variation in *CYP2C9* gene can have a significant effect on the outcome of treatment, particularly for drugs with a narrow therapeutic index like warfarin.[@b15-pgpm-12-015]

In humans, *CYP2C9* gene has been mapped to chromosome 10q24.2 and covers \>55 kilobases (kb).[@b16-pgpm-12-015],[@b17-pgpm-12-015] Polymorphisms of *CYP2C9* coding region have been extensively studied, and over 30 alleles have been recognized.[@b18-pgpm-12-015] The most common *CYP2C9* allele, *CYP2C9* \* 1, is considered to be a wild-type genotype, whereas the *CYP2C9* \* 2 and \* 3 alleles involve the single-nucleotide polymorphisms (SNPs) of Arg144Cys and Ile359Leu, respectively. Both the *CYP2C9* \* 2 and \* 3 alleles play an important role in the metabolic activity of warfarin.[@b19-pgpm-12-015]

In the promoter region of *CYP2C9*, a variable number tandem repeat (VNTR) polymorphism is located 4 kb upstream from the translation site, affecting the expression of *CYP2C9* mRNA in human liver. Three types of fragments were detected: short allele (p-VNTR-S) (417--438 bp), medium allele (p-VNTR-M) (446--488 bp), and long allele (p-VNTR-L) (512--522 bp). Of these fragments, p-VNTR-S has been found to decrease the activity of allelic promoters and, in turn, mRNA expression.[@b20-pgpm-12-015] These VNTR polymorphisms can regulate gene expression in a number of ways: inhibiting or promoting gene expression by modifying transcription factors or other binding site proteins; and change in the structure of the DNA, such as the variation in the distance between the functional units.[@b21-pgpm-12-015],[@b22-pgpm-12-015] VNTR polymorphisms often have an effect on gene expression as well as the increased risk of disease.[@b23-pgpm-12-015]--[@b28-pgpm-12-015]

The goal of the present study was to demonstrate the effects of *CYP2C9* (pVNTR) polymorphism on the risk of cardiovascular disease and the variability of warfarin dose requirements and sensitivity. Consequently, this study contributes to efforts to individualize dosing regimens in the Jordanian population.

Patients and methods
====================

Subjects
--------

Ethical approval for this study was obtained from the Human Research Committees at Jordan University of Science and Technology in Irbid and the Royal Medical Services in Amman. This study was also conducted in accordance with the Declaration of Helsinki. All patients were recruited from anticoagulation clinics within the Queen Alia Heart Institute in Amman, after they gave their written informed consent. Patients taking *CYP2C9*-inducing drugs or those receiving concomitant treatment known to interact with warfarin or recorded clinical data lost, pregnant women, and alcohol abuse were excluded. In total, 416 subjects (205 healthy controls free of any cardiovascular disease and 211 cardiovascular patients) who were aged ≥18 years, who had been receiving warfarin for at least 3 months, and who gave written approval were included in this study.

Data collection and follow-up time
----------------------------------

The blood samples were collected for the determination of the venous INR and p-VNTR of the *CYP2C9* genotype. During patients' clinical visits, demographic data on gender, age, and body mass index were recorded, as well as indications for warfarin treatment, target INR (INR values were reviewed in medical records from January 2014 to November 2015), average weekly doses of warfarin required to reach the therapeutic INR, medical problems, and concurrent medications. In this study, the required warfarin dose and INR values were recorded in two stages: the first stage is at the beginning of the therapy and called initiation phase, and the second stage is when the INR values reach the stable point, where the INR values are within the therapeutic range for at least three consecutive visits and this stage is called the stabilization phase of therapy.

Outcome measures
----------------

The patients in this study were divided into two categories during the initiation and stabilization of therapy. The first category was sensitivity to warfarin according to Klein et al study (2009):[@b29-pgpm-12-015] patients in this category were defined as patients with resistance to warfarin needing a high dose of warfarin to reach therapeutic INR (\>49 mg/week), normal patients requiring an intermediate dose (21--49 mg/week), and sensitive patients needing a low dose of warfarin (\<21 mg/week). Based on Higashi et al's (2002) study,[@b30-pgpm-12-015] the second category included response to warfarin and was subdivided into good responders (INR value within the therapeutic range), poor responders (INR value below the target), and ultra-responders (INR above the target range).

Genotyping
----------

Leukocyte DNA was extracted with the Gentra Pure gene Blood kit according to the manufacturing protocols (Promega Corporation, Fitchburg, WI, USA). The concentration and purity of the extracted DNA were evaluated using the NanoDrop 1000^®^ spectrophotometer.

DNA samples were amplified by PCR in a final volume of 25 µL, each with 1.5 µL of primer, 2 µL of genomic DNA, 12.5 µL of master mix, and 9.5 µL of nuclease-free water.

The sequences for the forward and reverse primers were 5′-TGTAGTCCCAGGTTGTCAAGAGG-3′ and 5′-CCAGTCTCTGTCTTTTCATCTCATTC-3′, respectively.[@b20-pgpm-12-015] The PCR conditions consisted of the initial denaturation at 95°C for 1 minute, 35 1-minute cycles (denaturation at 94°C, annealing at 60°C, and extension at 72°C) and a final 5-minute extension at 72°C. Known genotype controls and DNA-free blank tubes were included with each batch of samples. The PCR products were visualized in 3% polyacrylamide gels stained with ethidium bromide.

Statistical analysis
--------------------

We used the Pearson chi-squared tests to assess the genetic association of p-VNTR and cardiovascular disease, and Hardy-Weinberg equilibrium (HWE) *P*-values for genotypic distribution were calculated via the Court lab-HW calculator. In order to assess which of the selected *CYP2C9* p-VNTR polymorphisms is associated with warfarin sensitivity and responsiveness, several statistical analyses of genetic correlation were carried out using SPSS version 21.0, including the chi-squared test and one-way ANOVA. Further, to study genotype-per-genotype association, we used post hoc multiple comparison test.

Results
=======

Patient characteristics
-----------------------

A total of 211 warfarin intake patients agreed to participate in this study. These 211 patients were included in this study to evaluate the association of *CYP2C9* (p-VNTR) genotype with increased risk of cardiovascular disease and its effect on the sensitivity and responsiveness of warfarin during the initiation phase of therapy in Jordanian population, of which only 132 patients reached the stabilization stage, and therefore, to evaluate the effect of this genotype on the sensitivity and responsiveness to warfarin during the stabilization phase of the therapy in Jordanian population.

Overall, 69.6% of the patients were good metabolizers, 15.2% were extensive metabolizers, and 15.2% were poor metabolizers. The mean age and the smoking status were found to differ significantly between these three groups, with *P*=0.019 and *P*\<0.0001, respectively. Patient demographics, indications for anticoagulation therapy, and warfarin dose requirements for each group are shown in [Table 1](#t1-pgpm-12-015){ref-type="table"}. The mean age of the control (n=205) was 37.3 with SD 13.8, 112 out of 205 were male and 67 were smokers.

Genotypic and allelic frequencies
---------------------------------

All samples were genotyped for p-VNTR polymorphism, which was previously reported to affect *CYP2C9* enzyme activity.[@b20-pgpm-12-015] Regarding the length of p-VNTR repeats in the *CYP2C9* promoter region, five different genotypes were identified. The subjects were categorized into depending on whether they possessed the short (p-VNTR-S, 417--438 bp), medium (p-VNTR-M, 446--488 bp), or long (p-VNTR-L, 512--522 bp) alleles.

These (p-VNTR) polymorphisms were in accordance with the HWE. Analysis of genotypes showed that there were seven (3.3%) subjects with the homozygous LL genotype, 58 (27.5%) subjects with the heterozygous ML genotype, five (2.4%) subjects with the homozygous SS genotype, 82 (38.8) subjects with the heterozygous MS genotype, and 59 (28%) subjects with the homozygous MM genotype ([Table 2](#t2-pgpm-12-015){ref-type="table"}). Allelic and genotypic frequencies differed significantly between patients and controls ([Table 2](#t2-pgpm-12-015){ref-type="table"}). The frequency of the MS genotype was 38.8% (82/211) in patients compared with 58.1% (119/205) in controls. Among the patients, the frequency of the ML genotype was 27.5% (58/211) compared with 14.6% (30/205) in controls (overall *P*-value \<0.001). Allelic and genotypic frequencies for *CYP2C9* p-VNTR polymorphism are shown in [Table 2](#t2-pgpm-12-015){ref-type="table"}.

Association of *CYP2C9* p-VNTR polymorphism with warfarin sensitivity during the initiation and stabilization phases of therapy
-------------------------------------------------------------------------------------------------------------------------------

There were no statistically significant differences between the doses required to reach the target INR during the initiation and stabilization phases of therapy and *CYP2C9* (p-VNTR) genotypes (*P*=0.192 and 0.966) ([Table 3](#t3-pgpm-12-015){ref-type="table"}).

Patients were referred to as sensitive, moderate, and resistant, according to the required dose needed to reach the target INR. The sensitive group showed a high frequency of the SS (20%) and LM (22.4%) genotypes, while the resistant group showed a higher frequency of the LL genotype (28.6%) only during the initiation phase of therapy with overall *P*-value \<0.001, whereas when we compared each separate genotype with these sensitive groups, no significant association was found ([Table 4](#t4-pgpm-12-015){ref-type="table"}). During the stabilization phase, no significant associations were found neither between the sensitive groups as a general value nor with each separate genotype with overall *P*-value =0.910 ([Table 5](#t5-pgpm-12-015){ref-type="table"}).

Association of *CYP2C9* p-VNTR polymorphism with warfarin responsiveness during the initiation and stabilization phases of therapy
----------------------------------------------------------------------------------------------------------------------------------

Based on warfarin responsiveness, patients were divided into three groups: poor, good, and ultra-responders. There were no significant differences between the frequencies for the different genotypes among the three groups, neither in the initiation phase (overall *P*=0.255) nor throughout the maintenance phase (overall *P*=0.350) of therapy ([Tables 6](#t6-pgpm-12-015){ref-type="table"} and [7](#t7-pgpm-12-015){ref-type="table"}).

There were no significant differences in the *CYP2C9* p-VNTR and the value of INR measured at the initial stage of therapy in 211 patients receiving warfarin (overall *P*=0.598) nor for INR values measured in 132 patients during the stabilization phase (overall *P*=0.466) ([Table 8](#t8-pgpm-12-015){ref-type="table"}).

Discussion
==========

In this study, we investigated and characterized the p-VNTR polymorphism of *CYP2C9* gene and its association with increased risk of cardiovascular disease and with warfarin sensitivity and responsiveness during the initiation and stabilization phases of warfarin therapy in a Jordanian population.

Sconce et al study exhibited that patients carrying *CYP2C9* variants have an altered ability to metabolize warfarin, resulting in an effect in the clearance of S-active warfarin metabolite and, therefore, alter the dose required to reaching the therapeutic INR.[@b31-pgpm-12-015] It has been extensively demonstrated that VNTRs affect gene expression[@b23-pgpm-12-015],[@b24-pgpm-12-015],[@b26-pgpm-12-015] and are associated with the risk of diseases such as Alzheimer's disease.[@b27-pgpm-12-015],[@b28-pgpm-12-015]

To our knowledge, although several SNP/haplotype studies of the *CYP2C9* promoter have been identified, none of them demonstrate the *CYP2C9* p-VNTR polymorphism and its effect on warfarin clearance, except Wang et al study.[@b20-pgpm-12-015],[@b32-pgpm-12-015]--[@b34-pgpm-12-015] Similarly, we evaluated the frequency of p-VNTR polymorphisms and their genetic associations with cardiovascular diseases, and this study revealed a significant association between these polymorphisms and the risk of developing cardiovascular disease. Allelic and genotypic frequencies differ significantly between patients and controls. We found the frequency of L allele was 17.1% (72/422) in patients compared with 7.8% (32/410) in controls (*P*\<0.001) ([Table 2](#t2-pgpm-12-015){ref-type="table"}).

To our knowledge, no studies demonstrate the relation between these polymorphisms and the risk of cardiovascular disease. Wang et al demonstrated that the p-VNTR-S allele reduces promoter activity of the *CYP2C9* enzyme in human liver.[@b20-pgpm-12-015] It has also been reported that p-VNTR-S allele is associated with a 25%--60% reduction in *CYP2C9* mRNA expression compared with p-VNTR-M or p-VNTR-L alleles.[@b20-pgpm-12-015] Consistent with these results, our results indicate that the p-VNTR genotype significantly affected warfarin sensitivity during the initiation of therapy, which could be the result of enzyme deactivation activity. We found that 20% of the warfarin-sensitive patients were homozygous for the short p-VNTR-S allele and 12.2% were heterozygous, p-VNTR-M/p-VNTR-S; therefore, these patients required a lower dose to achieve a therapeutic INR. Homozygous p-VNTR-S genotypic frequency in our population (2.4%) is lesser than that in African--American population (5.1%).[@b20-pgpm-12-015] Finally, during the stabilization phase of therapy, no significant differences were found between these groups and their genotype frequencies ([Tables 4](#t4-pgpm-12-015){ref-type="table"} and [5](#t5-pgpm-12-015){ref-type="table"}).

To our knowledge, no studies have evaluated the association between *CYP2C9* p-VNTR polymorphism and the response to warfarin using the INR outcome measures. In the current study, no association between this polymorphism and the response to warfarin during the initiation and maintenance phases confirmed the therapy ([Tables 6](#t6-pgpm-12-015){ref-type="table"} and [7](#t7-pgpm-12-015){ref-type="table"}). Wang et al demonstrated that the p-VNTR-S polymorphism is present in high linkage disequilibrium with the *CYP2C9* \* 3 loss-of-function allele, so the effect of p-VNTR-S on warfarin metabolism appears to be restricted. Therefore, p-VNTR-S is not assessed as a biomarker for warfarin dosing and further studies are required to confirm its independent effects on warfarin metabolism.[@b20-pgpm-12-015]

Conclusion
==========

Our data show a significant association between the *CYP2C9* p-VNTR polymorphism and the risk of cardiovascular disease as well as the association between this polymorphism and the sensitivity to warfarin during the initiation phase of treatment. However, no association was found between this polymorphism and warfarin responsiveness or between the INR result and the required warfarin dose to reach the therapeutic INR, either during the initiation or the maintenance of therapy. To confirm our results, further analyses with a larger number of samples and different populations are required.
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###### 

Demographics and clinical characteristics of 211 cardiovascular patients treated with warfarin at the Queen Alia Heart Institute

  Category                                                        Subcategory       Poor metabolizer   Good metabolizers   Extensive metabolizers   *P*-value[\*](#tfn1-pgpm-12-015){ref-type="table-fn"}
  --------------------------------------------------------------- ----------------- ------------------ ------------------- ------------------------ -------------------------------------------------------
                                                                                                                                                    
  Demographics                                                    Patients (N, %)   (32/211) 15.2%     (147/211) 69.6%     (32/211) 15.2%           
  Age[a](#tfn2-pgpm-12-015){ref-type="table-fn"}, years \[%\]     57.2 \[17.1\]     54.7 \[14.8\]      47.2 \[14.7\]       0.019                    
  BMI[a](#tfn2-pgpm-12-015){ref-type="table-fn"}, kg/m^2^ \[%\]   28.1 \[6.2\]      27.8 \[4.9\]       27.6 \[3.5\]        0.732                    
  Smoking (N, %)                                                  (15/32) 46.9%     (42/147) 28.6%     (16/32) 50.0%       \<0.0001                 
  Male                                                            59.4%             51.0%              65.6%               0.27                     
  Female                                                          40.6%             49.0%              34.4%                                        
  Concomitant disease                                             Comorbidity       65.6%              68.7%               53.1%                    0.075
  Hypertension                                                    40.6%             42.2%              18.8%               0.046                    
  Diabetes mellitus                                               21.9%             21.8%              21.9%               1.0                      
  CHD                                                             31.3%             25.9%              28.1%               0.814                    
  Thyroid                                                         0%                3.4%               3.1%                0.57                     
  Lipid                                                           3.1%              6.8%               3.1%                0.55                     
  Medication                                                      Aspirin           59.4%              66%                 75%                      0.411
  Indication of treatment                                         MVR               18.8%              12.9%               21.9%                    0.163
  AVR                                                             6.3%              23.8%              21.9%                                        
  AF                                                              37.5%             17.7%              18.8%                                        
  DVR                                                             18.7%             23.1%              25.0%                                        
  Others                                                          18.7%             22.5%              12.4%                                        
  Target INR                                                      2--3              46.9%              38.8%               37.5%                    0.69
  2.5--3.5                                                        53.1%             61.2%              62.5%                                        
  Mean INR[a](#tfn2-pgpm-12-015){ref-type="table-fn"}                               2.8 \[0.73\]       2.4 \[0.75\]        2.5 \[0.85\]             0.027

**Notes:**

*P*-value \<0.05 is considered significant.

Mean SD in square brackets.

**Abbreviations:** AF, atrial fibrillation; AVR, aortic valve replacement; BMI, body mass index; CHD, chronic heart disease; DVR, double valve replacement; INR, international normalized ratio; MVR, mitral valve replacement.

###### 

Allelic and genotypic frequencies for the p-VNTR polymorphism, in 205 controls and 211 Jordanian cardiovascular patients

  Genotype and allele   Patients          Control           *P*-value[a](#tfn4-pgpm-12-015){ref-type="table-fn"}   Overall *P*-value[a](#tfn4-pgpm-12-015){ref-type="table-fn"}
  --------------------- ----------------- ----------------- ------------------------------------------------------ --------------------------------------------------------------
  SS                    (5/211) 2.4%      (1/205) 0.5%      0.271                                                  \<0.0001
  MM                    (59/211) 28%      (54/205) 26.3%    0.841                                                  
  LL                    (7/211) 3.3%      (1/205) 0.5%      0.133                                                  
  MS                    (82/211) 38.8%    (119/205) 58.1%   0.045                                                  
  ML                    (58/211) 27.5%    (30/205) 14.6%    0.045                                                  
  S                     (92/422) 21.8%    (121/410) 29.5%   \<0.0001                                               \<0.0001
  M                     (258/422) 61.1%   (257/410) 62.7%   0.980                                                  
  L                     (72/422) 17.1%    (32/410) 7.8%     0.034                                                  

**Note:**

Chi-squared test with *P*-value \<0.05 is considered significant.

**Abbreviation:** p-VNTR, promoter variable number tandem repeat.

###### 

Association of *CYP2C9* p-VNTR polymorphism with variability on required warfarin

  ----------------- ------------- ----------------- --------- ------------------------------------------------------ -------------------------------------------------------------- ------------------ --------- ------------------------------------------------------ -------------------------------------------------------------- ------- -------
  Polymorphism      Genotype      Initiation dose   95% CI    *P*-value[a](#tfn6-pgpm-12-015){ref-type="table-fn"}   Overall *P*-value[a](#tfn6-pgpm-12-015){ref-type="table-fn"}   Maintenance dose   95% CI    *P*-value[a](#tfn6-pgpm-12-015){ref-type="table-fn"}   Overall *P*-value[a](#tfn6-pgpm-12-015){ref-type="table-fn"}           
  Lower bound       Upper bound                                                                                                                                                                                                                                                                                                                
  *CYP2C9/p-VNTR*   SS            33.8600           16.4615   51.2585                                                0.969                                                          0.192              33.1500   28.4751                                                94.7751                                                        0.982   0.966
  MM                36.4780       33.1357           39.8203   0.829                                                  38.1206                                                        32.2087            44.0325   0.979                                                                                                                         
  LL                40.6463       33.7602           47.5325   1                                                      36.0167                                                        17.6241            54.4092   0.981                                                                                                                         
  LM                35.8793       31.1840           40.5746   0.751                                                  39.2184                                                        32.3301            46.1068   0.998                                                                                                                         
  MS                41.0143       22.6276           59.4010   0.751                                                  39.6346                                                        34.8483            44.4209   0.998                                                                                                                         
  ----------------- ------------- ----------------- --------- ------------------------------------------------------ -------------------------------------------------------------- ------------------ --------- ------------------------------------------------------ -------------------------------------------------------------- ------- -------

**Note:**

One-way ANOVA with *P*-value \<0.05 is considered significant, mean doses.

**Abbreviation:** p-VNTR, promoter variable number tandem repeat.

###### 

Association of *CYP2C9* p-VNTR polymorphism with warfarin sensitivity during the initiation phase of therapy of 211 cardiovascular patients treated with warfarin

  Polymorphism                                           Genotype        Sensitive       Moderate        Resistance    Overall *P*-value[a](#tfn8-pgpm-12-015){ref-type="table-fn"}
  ------------------------------------------------------ --------------- --------------- --------------- ------------- --------------------------------------------------------------
  p-VNTR                                                 SS              (1/5) 20.0%     (3/5) 60.0%     (1/5) 20.0%   \<0.001
  *P*-value[a](#tfn8-pgpm-12-015){ref-type="table-fn"}   0.76            0.62            0.76                          
  MM                                                     (8/59) 13.6%    (43/59) 72.9%   (8/59) 13.6%                  
  *P*-value[a](#tfn8-pgpm-12-015){ref-type="table-fn"}   0.69            0.55            0.69                          
  LL                                                     (0/0) 0.0%      (5/7) 71.4%     (2/7) 28.6%                   
  *P*-value[a](#tfn8-pgpm-12-015){ref-type="table-fn"}   0.27            0.92            0.32                          
  LM                                                     (13/58) 22.4%   (37/8) 63.8%    (8/58) 13.8%                  
  *P*-value[a](#tfn8-pgpm-12-015){ref-type="table-fn"}   0.07            0.27            0.84                          
  MS                                                     (10/82) 12.2%   (59/82) 71.9%   (13/82) 15.9%                 
  *P*-value[a](#tfn8-pgpm-12-015){ref-type="table-fn"}   0.32            0.53            0.84                          

**Note:**

Chi-squared test with *P*-value \<0.05 is considered significant.

**Abbreviation:** p-VNTR, promoter variable number tandem repeat.

###### 

Association of *CYP2C9* p-VNTR polymorphism with warfarin sensitivity during the stabilization phase of therapy of 132 cardiovascular patients treated with warfarin

  Polymorphism                                            Genotype       Sensitive       Moderate        Resistance   Overall *P*-value[a](#tfn10-pgpm-12-015){ref-type="table-fn"}
  ------------------------------------------------------- -------------- --------------- --------------- ------------ ---------------------------------------------------------------
  p-VNTR                                                  SS             (0/2) 0.0%      (2/0) 100.0%    (0/2) 0.0%   0.910
  *P*-value[a](#tfn10-pgpm-12-015){ref-type="table-fn"}   0.55           0.27            0.42                         
  MM                                                      (6/34) 17.6%   (20/34) 58.9%   (8/34) 23.5%                 
  *P*-value[a](#tfn10-pgpm-12-015){ref-type="table-fn"}   0.42           0.62            0.92                         
  LL                                                      (0/6) 0.0%     (5/6) 83.3%     (1/6) 16.7%                  
  *P*-value[a](#tfn10-pgpm-12-015){ref-type="table-fn"}   0.32           0.27            0.69                         
  LM                                                      (5/38) 13.2%   (23/38) 60.5%   (10/38) 26.3%                
  *P*-value[a](#tfn10-pgpm-12-015){ref-type="table-fn"}   0.92           0.84            0.69                         
  MS                                                      (7/52) 11.8%   (32/52) 62.7%   (13/52) 25.4%                
  *P*-value[a](#tfn10-pgpm-12-015){ref-type="table-fn"}   1              0.92            0.84                         

**Note:**

Chi-squared test with *P*-value \<0.05 is considered significant.

**Abbreviation:** p-VNTR, promoter variable number tandem repeat.

###### 

Association of *CYP2C9* p-VNTR polymorphism with response to warfarin during the initiation phase of therapy of 211 cardiovascular patients treated with warfarin

  Polymorphism                                            Genotype        Poor responder   Good responder   Ultra-responder   Overall *P*-value[a](#tfn12-pgpm-12-015){ref-type="table-fn"}
  ------------------------------------------------------- --------------- ---------------- ---------------- ----------------- ---------------------------------------------------------------
  p-VNTR                                                  SS              (2/5) 40.0%      (3/5) 60.0%      (0/5) 0.0%        0.255
  *P*-value[a](#tfn12-pgpm-12-015){ref-type="table-fn"}   0.92            0.55             0.37                               
  MM                                                      (27/59) 45.8%   (27/59) 45.8%    (5/59) 8.5%                        
  *P*-value[a](#tfn12-pgpm-12-015){ref-type="table-fn"}   0.42            1                0.23                               
  LL                                                      (0/0) 0.0%      (5/7) 71.4%      (2/7) 28.6%                        
  *P*-value[a](#tfn12-pgpm-12-015){ref-type="table-fn"}   0.02            0.16             0.19                               
  LM                                                      (21/58) 36.2%   (30/8) 51.7%     (7/58) 12.1%                       
  *P*-value[a](#tfn12-pgpm-12-015){ref-type="table-fn"}   0.27            0.23             0.84                               
  MS                                                      (38/82) 46.3%   (31/82) 37.8%    (13/82) 15.9%                      
  *P*-value[a](#tfn12-pgpm-12-015){ref-type="table-fn"}   0.23            0.07             0.32                               

**Note:**

Chi-squared test with *P*-value \<0.05 is considered significant.

**Abbreviation:** p-VNTR, promoter variable number tandem repeat.

###### 

Association of *CYP2C9* p-VNTR polymorphism with response to warfarin during the stabilization phase of therapy of 132 cardiovascular patients treated with warfarin

  Polymorphism                                            Genotype       Poor responder   Good responder   Ultra-responder   Overall *P*-value[a](#tfn14-pgpm-12-015){ref-type="table-fn"}
  ------------------------------------------------------- -------------- ---------------- ---------------- ----------------- ---------------------------------------------------------------
  p-VNTR                                                  SS             (0/2) 0.0%       (2/2) 100.0%     (0/2) 0.0%        0.350
  *P*-value[a](#tfn14-pgpm-12-015){ref-type="table-fn"}   0.69           0.62             0.76                               
  MM                                                      (4/34) 11.8%   (26/34) 76.5%    (4/34) 11.8%                       
  *P*-value[a](#tfn14-pgpm-12-015){ref-type="table-fn"}   0.19           0.01             0.02                               
  LL                                                      (1/6) 16.7%    (5/6) 83.3%      (0/6) 0.0%                         
  *P*-value[a](#tfn14-pgpm-12-015){ref-type="table-fn"}   0.32           0.69             0.62                               
  LM                                                      (2/38) 5.3%    (35/38) 92.1%    (1/38) 2.6%                        
  *P*-value[a](#tfn14-pgpm-12-015){ref-type="table-fn"}   0.62           0.42             0.48                               
  MS                                                      (2/52) 3.8%    (49/52) 94.2%    (1/52) 1.9%                        
  *P*-value[a](#tfn14-pgpm-12-015){ref-type="table-fn"}   0.27           0.11             0.23                               

**Note:**

Chi-squared test with *P*-value \<0.05 is considered significant.

**Abbreviation:** p-VNTR, promoter variable number tandem repeat.

###### 

Association of *CYP2C9* p-VNTR polymorphism with INR treatment outcome

  Polymorphism      Genotype   Initiation INR   95% CI   *P*-value[a](#tfn16-pgpm-12-015){ref-type="table-fn"}   Overall *P*-value[a](#tfn16-pgpm-12-015){ref-type="table-fn"}   Maintenance INR   95% CI   Upper bound   Overall *P*-value[a](#tfn16-pgpm-12-015){ref-type="table-fn"}           
  ----------------- ---------- ---------------- -------- ------------------------------------------------------- --------------------------------------------------------------- ----------------- -------- ------------- --------------------------------------------------------------- ------- -------
  *CYP2C9/p-VNTR*   SS         2.32             1.2613   3.3787                                                  0.477                                                           0.598             2.85     −5.4090       11.1090                                                         0.997   0.466
  MM                2.34       2.1444           2.5454   0.969                                                   2.7                                                             2.5625            2.8464   1                                                                                     
  LL                3.16       2.0133           4.3009   0.083                                                   2.5                                                             2.0450            2.9550   0.825                                                                                 
  LM                2.48       2.3006           2.6649   0.253                                                   2.64                                                            2.4986            2.7762   0.998                                                                                 
  MS                2.48       2.3138           2.6496   0.232                                                   2.73                                                            2.6447            2.8245   0.934                                                                                 

**Note:**

One-way ANOVA with *P*-value \<0.05 is considered significant, mean INR.

**Abbreviations:** p-VNTR, promoter variable number tandem repeat; INR, international normalized ratio.
